Joaquin Hinojosa
Overview
Explore the profile of Joaquin Hinojosa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
734
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gisbert-Ferrandiz L, Llau J, Ortiz-Masia D, Cosin-Roger J, Macias-Ceja D, Hinojosa J, et al.
Nutrients
. 2024 Oct;
16(20).
PMID: 39458479
Background: Vitamin D, through the activation of its receptor (VDR), plays an immunomodulatory role in the gastrointestinal tract. Single-nucleotide polymorphisms (SNPs) in the VDR gene have been associated with Crohn's...
2.
Fuxman C, Sicilia B, Linares M, Garcia-Lopez S, Gonzalez Sueyro R, Gonzalez-Lamac Y, et al.
Gastroenterol Hepatol
. 2023 Feb;
46 Suppl 1:S1-S56.
PMID: 36731724
Introduction: Ulcerative colitis (UC) is a chronic inflammatory disease that compromises the colon, affecting the quality of life of individuals of any age. In practice, there is a wide spectrum...
3.
Guijarro L, Cano-Martinez D, Toledo-Lobo M, Ruiz-Llorente L, Chaparro M, Guerra I, et al.
Biomedicines
. 2022 Mar;
10(3).
PMID: 35327530
Background: Recently, increased tissue levels of AIF-1 have been shown in experimental colitis, supporting its role in intestinal inflammation. Therefore, we studied the levels of AIF-1 in Crohn’s disease (CD)....
4.
Calafat M, Manosa M, Ricart E, Nos P, Iglesias-Flores E, Vera I, et al.
J Crohns Colitis
. 2021 Dec;
16(6):946-953.
PMID: 34864947
Background And Aims: Immunomediated adverse events [IAEs] are the most frequently reported infliximab [IFX]-related adverse events. Combination therapy may reduce their incidence, although this strategy is not recommended in elderly...
5.
Guijarro L, Cano-Martinez D, Toledo-Lobo M, Salinas P, Chaparro M, Gomez-Lahoz A, et al.
Biomed Pharmacother
. 2021 Oct;
144:112239.
PMID: 34601192
Inflammatory bowel diseases (IBD), represented by ulcerative colitis (UC) and Crohn's disease (CD), are characterized by chronic inflammation of the gastrointestinal tract, what leads to diarrhea, malnutrition, and weight loss....
6.
Casanova M, Chaparro M, Nantes O, Manuel Benitez J, Rojas-Feria M, Castro-Poceiro J, et al.
Aliment Pharmacol Ther
. 2021 May;
53(12):1277-1288.
PMID: 33962482
Background: The long-term outcome of patients after antitumour necrosis factor alpha (anti-TNF) discontinuation is not well known. Aims: To assess the risk of relapse in the long-term after anti-TNF discontinuation....
7.
Chaparro M, Garre A, Iborra M, Sierra-Ausin M, Barreiro-de Acosta M, Fernandez-Clotet A, et al.
J Crohns Colitis
. 2021 Apr;
15(11):1846-1851.
PMID: 33860795
Background And Aims: The development programm UNIFI has shown promising results of ustekinumab in ulcerative colitis [UC] treatment which should be confirmed in clinical practice. We aimed to evaluate the...
8.
Sicilia B, Garcia-Lopez S, Gonzalez-Lama Y, Zabana Y, Hinojosa J, Gomollon F
Gastroenterol Hepatol
. 2020 Aug;
43 Suppl 1:1-57.
PMID: 32807301
Introduction: Since the first edition of the Guidelines was published in 2013, much information has been generated around the treatment of ulcerative colitis, and new drugs and action protocols have...
9.
Iborra M, Beltran B, Fernandez-Clotet A, Iglesias-Flores E, Navarro P, Rivero M, et al.
Aliment Pharmacol Ther
. 2020 Aug;
52(6):1017-1030.
PMID: 32770851
Background: Data on the long-term administration of ustekinumab in recommended doses are limited. Aim: To assess the real-world, long-term effectiveness of ustekinumab in refractory Crohn's disease (CD). Methods: Multi-centre study...
10.
Chaparro M, Guerra I, Iborra M, Cabriada J, Bujanda L, Taxonera C, et al.
Eur J Gastroenterol Hepatol
. 2020 Apr;
32(5):588-596.
PMID: 32251204
Aims: The aims of this study were (a) to know the kinetics of antitumor necrosis factor (TNF) drug serum levels during the induction phase in patients with Crohn's disease; (b)...